Tbio | Complement decay-accelerating factor |
(Microbial infection) Acts as a receptor for coxsackievirus A21, coxsackieviruses B1, B3 and B5 (PubMed:9151867). Acts as a receptor for human enterovirus 70 and D68 (Probable) (PubMed:8764022). Acts as a receptor for human echoviruses 6, 7, 11, 12, 20 and 21 (PubMed:7525274).
This gene encodes a glycoprotein involved in the regulation of the complement cascade. Binding of the encoded protein to complement proteins accelerates their decay, thereby disrupting the cascade and preventing damage to host cells. Antigens present on this protein constitute the Cromer blood group system (CROM). Alternative splicing results in multiple transcript variants. The predominant transcript variant encodes a membrane-bound protein, but alternatively spliced transcripts may produce soluble proteins. [provided by RefSeq, Jul 2014]
This gene encodes a glycoprotein involved in the regulation of the complement cascade. Binding of the encoded protein to complement proteins accelerates their decay, thereby disrupting the cascade and preventing damage to host cells. Antigens present on this protein constitute the Cromer blood group system (CROM). Alternative splicing results in multiple transcript variants. The predominant transcript variant encodes a membrane-bound protein, but alternatively spliced transcripts may produce soluble proteins. [provided by RefSeq, Jul 2014]
Comments
Disease | Target Count | Z-score | Confidence |
---|---|---|---|
Amphetamine-Related Disorders | 74 | 0.0 | 0.0 |
Endometriosis | 540 | 0.0 | 0.0262388362581057 |
Protein-Losing Enteropathies | 4 | 0.0 | 0.0 |
MTVARPSVPAALPLLGELPRLLLLVLLCLPAVWGDCGLPPDVPNAQPALEGRTSFPEDTVITYKCEESFV 1 - 70 KIPGEKDSVICLKGSQWSDIEEFCNRSCEVPTRLNSASLKQPYITQNYFPVGTVVEYECRPGYRREPSLS 71 - 140 PKLTCLQNLKWSTAVEFCKKKSCPNPGEIRNGQIDVPGGILFGATISFSCNTGYKLFGSTSSFCLISGSS 141 - 210 VQWSDPLPECREIYCPAPPQIDNGIIQGERDHYGYRQSVTYACNKGFTMIGEHSIYCTVNNDEGEWSGPP 211 - 280 PECRGKSLTSKVPPTVQKPTTVNVPTTEVSPTSQKTTTKTTTPNAQATRSTPVSRTTKHFHETTPNKGSG 281 - 350 TTSGTTRLLSGHTCFTLTGLLGTLVTMGLLT 351 - 381 //